ImmunityBio, Inc. (IBRX)
Automate Your Wheel Strategy on IBRX
With Tiblio's Option Bot, you can configure your own wheel strategy including IBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline
Published: April 03, 2026 by: PRNewsWire
Sentiment: Neutral
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class Period: January 19, 2026 through March 24, 2026 Deadline to Seek Lead Plaintiff Status: May 26, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead biologic product, Anktiva.
Read More
IBRX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: April 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v.
Read More
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
Published: April 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class Period: January 19, 2026 through March 24, 2026 Deadline to Seek Lead Plaintiff Status: May 26, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's lead biologic product, Anktiva.
Read More
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
Published: April 01, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, April 1, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class Action
Published: April 01, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). ImmunityBio investors have until May 26, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LO.
Read More
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Published: March 31, 2026 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO, March 31, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v.
Read More
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 31, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before May 26, 2026.
Read More
Law Offices of Frank R. Cruz Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class Action
Published: March 31, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class Action.
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
Published: March 31, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 31, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, inclusive. Should You Join The ImmunityBio Class Action Lawsuit?
Read More
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
Published: March 30, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and March 24, 2026. The lawsuit follows news that the FDA sent a warning letter to the company concerning claims made by its executive chairman and Chief Scientific and Medical Officer (Dr. Patrick Soon-Shiong) regarding ImmunityBio's lead biologic product (Anktiva), which the FDA said were misleading efficacy claims.
Read More
ImmunityBio ALERT: $IBRX Investors Who Lost Money Should Contact Block & Leviton By May 26th To Potentially Recover Losses
Published: March 30, 2026 by: Newsfile Corp
Sentiment: Neutral
Boston, Massachusetts--(Newsfile Corp. - March 30, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) and certain of its executives. Investors who have lost money in their ImmunityBio investment should contact the firm to learn more about how they might recover those losses.
Read More
Securities Fraud Investigation Into ImmunityBio, Inc. (IBRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Published: March 30, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON IMMUNITYBIO, INC. (IBRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On Ma.
Read More
IBRX Class Action Reminder: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ImmunityBio, Inc. Securities Fraud Class Action
Published: March 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product.
Read More
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Published: March 27, 2026 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO, March 27, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit. Captioned Douglas v.
Read More
IBRX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ImmunityBio, Inc.
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product.
Read More
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of investors that bought securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). Immunity Bio investors have until May 26, 2026 to file a lead plaintiff motion.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
Published: March 27, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
Published: March 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
A lawsuit has been filed against ImmunityBio. ImmunityBio investors should contact Block & Leviton to possibly recover losses from their $IBRX investment.
Read More
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
Read More
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report?
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?
Read More
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
Published: March 25, 2026 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio stock sinks 21% after the FDA flags misleading claims on cancer drug Anktiva, citing exaggerated benefits and inadequate risk disclosures.
Read More
ImmunityBio stock price crash: buy the dip or sell the rip?
Published: March 24, 2026 by: Invezz
Sentiment: Negative
ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a scathing warning letter over the firm's promotional tactics. Investors bailed on IBRX as regulators alleged the company and its billionaire founder, Dr. Patrick Soon-Shiong, used a TV ad and a high-profile podcast to make “false or misleading” claims about Anktiva.
Read More
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
Published: March 24, 2026 by: Zacks Investment Research
Sentiment: Positive
IBRX stock jumps after China approves Anktiva combo therapy for bladder cancer, marking its first Asia nod and expanding global reach to 34 markets.
Read More
ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Published: March 24, 2026 by: Newsfile Corp
Sentiment: Neutral
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of ImmunityBio, Inc. (NASDAQ: IBRX). The investigation focuses on ImmunityBio executive officers and whether investor losses may be recovered under federal securities laws.
Read More
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive
ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.
Read More
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
Published: March 20, 2026 by: Business Wire
Sentiment: Neutral
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People's Republic of China has granted regulatory approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln). The approval establishes ANKTIVA's initial presence in Asia and reflects the Company's strategy to expand global access through reliance-based regulatory pathways. In Macau, ANKTIVA is approved in co.
Read More
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties.
Read More
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
Published: February 25, 2026 by: Benzinga
Sentiment: Positive
ImmunityBio Inc. (NASDAQ: IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth.
Read More
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate
Published: February 25, 2026 by: Benzinga
Sentiment: Positive
Source: Benzinga
Read More
Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More
Published: February 23, 2026 by: Seeking Alpha
Sentiment: Neutral
The Undercovered Dozen series spotlights 12 less-covered stocks highlighted in recent Seeking Alpha articles. This week's edition covers articles published between Feb. 13 and Feb. 19, offering fresh investment ideas. The series aims to inspire discussion and help investors discover overlooked opportunities in the market.
Read More
About ImmunityBio, Inc. (IBRX)
- IPO Date 2015-07-28
- Website https://immunitybio.com
- Industry Biotechnology
- CEO Richard Gerald Adcock
- Employees 671